Q-omics provides the consensus-scored TRGC1 profile across patient tissues and cancer cell-line models. TRGC1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRGC1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TRGC1 RNA expression shows 13,317 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, COAD, and LSCC as cancer lineages where TRGC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGC1 survival associations across molecular data types. TRGC1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGC1 RNA expression–survival associations across cancer types. High TRGC1 expression shows unfavorable associations in UVM, but favorable associations in SKCM, UCEC, OV, CESC and LIHC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRGC1 RNA expression.
This table summarizes TRGC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRGC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGC1 shows lower tumor expression in COAD, LUAD, KIRP, LUSC and THCA and higher tumor expression in PRAD. The COAD box plot shows higher TRGC1 RNA expression in normal versus tumor tissue (log2 FC = −0.643, t-test p < 0.001).
This table shows molecular features associated with TRGC1 in patient tissues and cancer cell lines. In patient samples, TRGC1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
